Pupil dilation linked to glaucoma progression

Article

In patients with open-angle glaucoma (OAG), the increase in intraocular pressure (IOP) caused by pharmacological pupillary dilation is related to the likelihood of future progression of glaucoma.

In patients with open-angle glaucoma (OAG), the increase in intraocular pressure (IOP) caused by pharmacological pupillary dilation is related to the likelihood of future progression of glaucoma, according to a report published in the September issue of the British Journal of Ophthalmology.

Ghada Siam and colleagues from Jefferson Medical College, Philadelphia, USA conducted a retrospective chart review of 100 eyes from 55 subjects with OAG who had had IOP measured before and after pharmacological pupillary dilation. Progressive visual field loss was defined as an increase of two or more stages with the glaucoma staging system 2 (GSS 2) and progressive deterioration of the disc was defined as an increased of two or more stages with the disc damage likelihood scale (DDLS). Mean follow-up time was 7.2 years.

The researchers found that 26 eyes demonstrated glaucomatous progression and the likelihood of progression was related to the amount of IOP increase following pharmacological pupillary dilation. For every 1 mmHg increase of IOP, the odds of progression increased by 24% (p=0.008). However, the likelihood of glaucoma progression was not related to baseline IOP.

It would seem that in patients with OAG, the amount of increase in IOP caused by pharmacological pupillary dilation is related to the likelihood of future glaucomatous progression.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.